BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37966258)

  • 21. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
    Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
    BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.
    Glod J; Arnaldez FI; Wiener L; Spencer M; Killian JK; Meltzer P; Dombi E; Derse-Anthony C; Derdak J; Srinivasan R; Linehan WM; Miettinen M; Steinberg SM; Helman L; Widemann BC
    Clin Cancer Res; 2019 Nov; 25(21):6302-6308. PubMed ID: 31439578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
    Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
    Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.
    Italiano A; Chen CL; Sung YS; Singer S; DeMatteo RP; LaQuaglia MP; Besmer P; Socci N; Antonescu CR
    BMC Cancer; 2012 Sep; 12():408. PubMed ID: 22974104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
    Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
    J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
    Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
    BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of nine cases, including uncommon features of a relatively under-recognized entity.
    Rekhi B; Michal M; Ergen FB; Roy P; Puls F; Haugland HK; Soylemezoglu F; Kosemehmetoglu K
    Ann Diagn Pathol; 2021 Dec; 55():151809. PubMed ID: 34482218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
    Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
    Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
    Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
    Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and lessons learned on remote trial implementation from TestBoston, a fully remote, longitudinal, large-scale COVID-19 surveillance study.
    Naz-McLean S; Kim A; Zimmer A; Laibinis H; Lapan J; Tyman P; Hung J; Kelly C; Nagireddy H; Narayanan-Pandit S; McCarthy M; Ratnaparkhi S; Rutherford H; Patel R; Dryden-Peterson S; Hung DT; Woolley AE; Cosimi LA
    PLoS One; 2022; 17(6):e0269127. PubMed ID: 35657813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
    Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
    Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDCT features of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours.
    Tirumani SH; Tirumani H; Jagannathan JP; Shinagare AB; Hornick JL; George S; Wagner AJ; Ramaiya NH
    Br J Radiol; 2014 Nov; 87(1043):20140476. PubMed ID: 25189191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
    Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
    Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.